FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Morton Neil (Last) (First) (Middle) 11975 EL CAMINO REAL, SUITE 300 (Street) SAN DIEGO CA 92130						Issuer Name and Ticker or Trading Symbol APRICUS BIOSCIENCES, INC. [APRI] Date of Earliest Transaction (Month/Day/Year) 06/01/2017 4. If Amendment, Date of Original Filed (Month/Day/Year)								(C	Relationship of Reporting Person(s) to Issuer Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) SVP, Chief Business Officer Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person			
(City)	(St	ate) (Z	Zip)													Form filed by More than One Reporting Person		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,			3. 4. Securities Ac Disposed Of (D) and 5)					Secur	icially d	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	()	A) or D)	Price	Repo		(Instr. 4)	(Instr. 4)
Common Stock 06/01/20						.017			A ⁽¹⁾		75,00	75,000 A		(2	1	62,118	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	on Date,	4. Transact Code (In 8)	le (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ative rities ired r osed . 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Shares		unt	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Award of 75,000 Restricted Stock Units ("RSUs") under the Issuer's Amended and Restated 2012 Stock Long Term Incentive Plan with half of the underlying shares vesting in the first open trading window following the Issuer's submission of Vitaros in the United States to the Food and Drug Administration ("FDA") and the other half of the underlying shares vesting in the first open trading window following the Issuer's receipt of marketing approval of Vitaros in the United States by the FDA, subject to the Reporting Person's continued employment or service to the Issuer through such date and subject to accelerated vesting upon a change in control of the Issuer.

2. Not applicable.

Remarks:

/s/ Richard W. Pascoe by power of attorney for Neil Morton

06/05/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).